FY2024 Earnings Forecast for CRBU Issued By Leerink Partnrs

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Investment analysts at Leerink Partnrs lifted their FY2024 earnings per share (EPS) estimates for Caribou Biosciences in a research note issued on Wednesday, November 6th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($1.69) for the year, up from their prior forecast of ($1.77). The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.71) per share. Leerink Partnrs also issued estimates for Caribou Biosciences’ Q4 2024 earnings at ($0.42) EPS, FY2025 earnings at ($1.64) EPS, FY2026 earnings at ($1.70) EPS, FY2027 earnings at ($1.69) EPS and FY2028 earnings at ($0.52) EPS.

Caribou Biosciences (NASDAQ:CRBU) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The company had revenue of $2.02 million during the quarter, compared to the consensus estimate of $3.37 million.

CRBU has been the topic of a number of other research reports. Royal Bank of Canada restated an “outperform” rating and set a $14.00 price target on shares of Caribou Biosciences in a research note on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Caribou Biosciences in a research note on Tuesday, September 3rd.

Caribou Biosciences Stock Up 4.1 %

NASDAQ CRBU opened at $2.79 on Monday. Caribou Biosciences has a 52 week low of $1.50 and a 52 week high of $8.33. The company has a 50 day moving average price of $2.02 and a 200 day moving average price of $2.27. The firm has a market cap of $252.63 million, a PE ratio of -1.69 and a beta of 2.26.

Institutional Investors Weigh In On Caribou Biosciences

A number of institutional investors have recently modified their holdings of the business. Intech Investment Management LLC acquired a new stake in Caribou Biosciences in the third quarter valued at approximately $43,000. China Universal Asset Management Co. Ltd. increased its holdings in Caribou Biosciences by 63.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,380 shares of the company’s stock worth $34,000 after acquiring an additional 6,768 shares in the last quarter. Exchange Traded Concepts LLC raised its position in Caribou Biosciences by 103.5% during the third quarter. Exchange Traded Concepts LLC now owns 82,494 shares of the company’s stock worth $162,000 after acquiring an additional 41,948 shares during the period. Green Alpha Advisors LLC grew its position in shares of Caribou Biosciences by 33.4% in the third quarter. Green Alpha Advisors LLC now owns 103,214 shares of the company’s stock valued at $202,000 after purchasing an additional 25,843 shares during the period. Finally, Point72 DIFC Ltd increased its stake in shares of Caribou Biosciences by 389.4% during the second quarter. Point72 DIFC Ltd now owns 30,157 shares of the company’s stock worth $49,000 after purchasing an additional 23,995 shares in the last quarter. 77.51% of the stock is currently owned by institutional investors and hedge funds.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.